Back to List View Graph View

Sodium glucose cotransporter-2 (SGLT2) inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of oral glucose-lowering drugs, developed for type 2 diabetes and now used more broadly as cardiorenal protective therapy.

Where the papers sit

33 papers from the last 6 months study Sodium glucose cotransporter-2 (SGLT2) inhibitors directly · updated from PubMed 11 Nov 2026

  • SGLT2 Safety and Outcomes

    SGLT2 inhibitor research is broadening from glycemic efficacy to safety, persistence, and cardiorenal outcomes across routine practice. Euglycaemic and diabetic ketoacidosis, urinary and genital infections, and discontinuation after hospitalization recur as practical concerns. Studies also test effects in elderly patients, monogenic diabetes, cirrhosis, neuropathy, and dementia risk, often using comparative or propensity-matched designs. The evidence supports wider clinical use but emphasizes patient selection, adverse-event recognition, and monitoring.

    10 papers · 30.3%

  • Real-World Diabetes Treatment

    GLP-1 receptor agonists and SGLT2 inhibitors are being judged increasingly through real-world use rather than trial efficacy alone. Recurring questions concern adherence, persistence, treatment costs, affordability, and time to insulin initiation. Comparative studies also examine survival, cognitive disorders, cancer incidence, and gastrointestinal safety. The field is moving toward value-based treatment selection while access and long-term safety remain uneven.

    9 papers · 27.3%

  • Cardiorenal Risk Prevention

    SGLT2 inhibitors are moving toward targeted prevention of heart failure and kidney decline in people with type 2 diabetes. Studies repeatedly assess estimated glomerular filtration rate, cardiovascular outcomes, and sustained use in older adults and chronic kidney disease. Combination prescribing with renin–angiotensin system inhibitors and finerenone is an emerging focus. Persistent treatment gaps in primary care remain a major implementation barrier.

    6 papers · 18.2%

  • Renal Protection and Safety

    Renal protection is the central theme, with studies examining proteinuria, kidney molecular markers, and medication-related problems in chronic kidney disease. SGLT2 inhibition is being evaluated beyond glucose lowering, including effects on vascular and inflammatory pathways in youth with type 1 diabetes. Evidence also extends to antiproteinuric treatment during atezolizumab plus bevacizumab therapy for hepatocellular carcinoma. The work supports broader kidney-focused use while leaving safety and context-specific effectiveness open.

    4 papers · 12.1%

  • Comparative Diabetes Therapies

    Treatment choices are shifting toward comparisons between GLP-1 receptor agonists and SGLT2 inhibitors, including their use together. Semaglutide is examined for seizure risk, atrial fibrillation populations, and early diabetic kidney disease, while canagliflozin provides a combination comparator. Real-world effectiveness and organ-specific outcomes are more prominent than glucose reduction alone. The main unresolved question is which patient profiles benefit most from each class or from combination therapy.

    4 papers · 12.1%

Papers

The 33 papers from the last 6 months that study Sodium glucose cotransporter-2 (SGLT2) inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

SGLT2 Safety and Outcomes (10)
  1. Disproportionate reporting of euglycaemic and diabetic ketoacidosis with SGLT-2 inhibitors across expanding cardiorenal indications: a cross-database study of FAERS and JADER. Frontiers in endocrinology · 4 Sept 2026 PMID 42694226
  2. Sodium-glucose cotransporter-2 inhibitor use and clinical outcomes in patients with cirrhosis: a propensity-matched real-world cohort study. European journal of gastroenterology & hepatology · 28 Aug 2026 PMID 42664456
  3. Sodium-glucose cotransporter 2 inhibitors for diabetic neuropathy: a protocol for a systematic review and meta-analysis. BMJ open · 27 Aug 2026 PMID 42660558
  4. Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42608294
  5. Safety and Tolerability of SGLT2 Inhibitors. Handbook of experimental pharmacology · 12 Aug 2026 PMID 42587086
  6. Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study. Diabetes, obesity & metabolism · 6 Aug 2026 PMID 42559753
  7. Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study. PloS one · 17 Jul 2026 PMID 42467634
  8. Comparative dementia risk associated with SGLT2 inhibitors versus DPP-4 inhibitors in patients with type 2 diabetes following traumatic brain injury: A propensity score-matched Cohort study. Diabetes research and clinical practice · 16 Jul 2026 PMID 42462925
  9. Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes. Annals of medicine · 13 Jul 2026 PMID 42439602
  10. Real-world evidence of urinary tract infections and genital tract infections with sodium-glucose cotransporter-2 inhibitors (SGLT2i) alone or in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type-2 diabetes mellitus in India. BMC endocrine disorders · 21 May 2026 PMID 42163184
Real-World Diabetes Treatment (9)
  1. Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808548
  2. Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study. PloS one · 24 Aug 2026 PMID 42636218
  3. Trends in utilization of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity. Diabetes research and clinical practice · 20 Aug 2026 PMID 42624330
  4. Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes. Diabetes research and clinical practice · 17 Aug 2026 PMID 42607727
  5. Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs. Diabetes, obesity & metabolism · 7 Aug 2026 PMID 42563367
  6. Availability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study. BMJ open · 24 Jul 2026 PMID 42498467
  7. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes, obesity & metabolism · 5 Jun 2026 PMID 42244136
  8. Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients. Urologic oncology · 1 Jun 2026 PMID 42224918
  9. Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study. Diabetes research and clinical practice · 27 May 2026 PMID 42202888
Cardiorenal Risk Prevention (6)
  1. Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors. Handbook of experimental pharmacology · 23 Sept 2026 PMID 42778649
  2. The SGLT2i Treatment Gap in UK Primary Care: A Cross-Sectional RWE Study of Prescribing in Clinical Practice. Diabetes, obesity & metabolism · 11 Sept 2026 PMID 42723263
  3. New Evidence in Heart Failure: 2026 Update. ESC heart failure · 1 Sept 2026 PMID 42679357
  4. Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry. Internal and emergency medicine · 26 Aug 2026 PMID 42642609
  5. Sustained Use of SGLT2 Inhibitors and Cardiovascular Outcomes in Older Adults: A Landmark Cohort Study. Diabetes, obesity & metabolism · 28 Jul 2026 PMID 42521604
  6. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes care · 20 May 2026 PMID 42160591
Renal Protection and Safety (4)
  1. Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
  2. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Science translational medicine · 22 Jul 2026 PMID 42485434
  3. Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors. Renal failure · 23 Jun 2026 PMID 42336367
  4. B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysis. Diabetes research and clinical practice · 15 Jun 2026 PMID 42297213
Comparative Diabetes Therapies (4)
  1. Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real world experience. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 26 Jun 2026 PMID 42362054
  2. Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. Neurology · 17 Jun 2026 PMID 42308439
  3. Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes and atrial fibrillation: a multicenter comparative effectiveness cohort study of cardiovascular and arrhythmic outcomes. Diabetes research and clinical practice · 29 May 2026 PMID 42214559
  4. Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease. Pakistan journal of pharmaceutical sciences · 22 May 2026 PMID 42170981

By study type

Clinical trials (2)
  1. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Science translational medicine · 22 Jul 2026 PMID 42485434
  2. Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease. Pakistan journal of pharmaceutical sciences · 22 May 2026 PMID 42170981
Observational studies and case reports (13)
  1. Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
  2. Sodium-glucose cotransporter-2 inhibitor use and clinical outcomes in patients with cirrhosis: a propensity-matched real-world cohort study. European journal of gastroenterology & hepatology · 28 Aug 2026 PMID 42664456
  3. Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study. PloS one · 24 Aug 2026 PMID 42636218
  4. Trends in utilization of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity. Diabetes research and clinical practice · 20 Aug 2026 PMID 42624330
  5. Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study. Diabetes, obesity & metabolism · 6 Aug 2026 PMID 42559753
  6. Sustained Use of SGLT2 Inhibitors and Cardiovascular Outcomes in Older Adults: A Landmark Cohort Study. Diabetes, obesity & metabolism · 28 Jul 2026 PMID 42521604
  7. Availability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study. BMJ open · 24 Jul 2026 PMID 42498467
  8. Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study. PloS one · 17 Jul 2026 PMID 42467634
  9. Comparative dementia risk associated with SGLT2 inhibitors versus DPP-4 inhibitors in patients with type 2 diabetes following traumatic brain injury: A propensity score-matched Cohort study. Diabetes research and clinical practice · 16 Jul 2026 PMID 42462925
  10. Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes. Annals of medicine · 13 Jul 2026 PMID 42439602
  11. Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors. Renal failure · 23 Jun 2026 PMID 42336367
  12. Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes and atrial fibrillation: a multicenter comparative effectiveness cohort study of cardiovascular and arrhythmic outcomes. Diabetes research and clinical practice · 29 May 2026 PMID 42214559
  13. Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study. Diabetes research and clinical practice · 27 May 2026 PMID 42202888
Human data, design not indexed (7)
  1. Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808548
  2. Disproportionate reporting of euglycaemic and diabetic ketoacidosis with SGLT-2 inhibitors across expanding cardiorenal indications: a cross-database study of FAERS and JADER. Frontiers in endocrinology · 4 Sept 2026 PMID 42694226
  3. Sodium-glucose cotransporter 2 inhibitors for diabetic neuropathy: a protocol for a systematic review and meta-analysis. BMJ open · 27 Aug 2026 PMID 42660558
  4. Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes. Diabetes research and clinical practice · 17 Aug 2026 PMID 42607727
  5. Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. Neurology · 17 Jun 2026 PMID 42308439
  6. B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease: a Japan Chronic Kidney Disease Database Extension analysis. Diabetes research and clinical practice · 15 Jun 2026 PMID 42297213
  7. Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. Diabetes care · 20 May 2026 PMID 42160591
Unclassified: not yet indexed with MeSH (11)
  1. Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors. Handbook of experimental pharmacology · 23 Sept 2026 PMID 42778649
  2. The SGLT2i Treatment Gap in UK Primary Care: A Cross-Sectional RWE Study of Prescribing in Clinical Practice. Diabetes, obesity & metabolism · 11 Sept 2026 PMID 42723263
  3. New Evidence in Heart Failure: 2026 Update. ESC heart failure · 1 Sept 2026 PMID 42679357
  4. Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry. Internal and emergency medicine · 26 Aug 2026 PMID 42642609
  5. Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42608294
  6. Safety and Tolerability of SGLT2 Inhibitors. Handbook of experimental pharmacology · 12 Aug 2026 PMID 42587086
  7. Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs. Diabetes, obesity & metabolism · 7 Aug 2026 PMID 42563367
  8. Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real world experience. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 26 Jun 2026 PMID 42362054
  9. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes, obesity & metabolism · 5 Jun 2026 PMID 42244136
  10. Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients. Urologic oncology · 1 Jun 2026 PMID 42224918
  11. Real-world evidence of urinary tract infections and genital tract infections with sodium-glucose cotransporter-2 inhibitors (SGLT2i) alone or in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type-2 diabetes mellitus in India. BMC endocrine disorders · 21 May 2026 PMID 42163184